L-748,337

**L-748,337** is a selective competitive antagonist of the **β3-adrenergic receptor (beta-3 adrenoceptor)**, exhibiting high affinity for the human β3 subtype and substantially lower affinity for β1 and β2 receptors [1][3][4][5][8][10]. - **Mechanism of action:** It blocks the β3-adrenergic receptor, thereby inhibiting receptor-mediated effects such as cAMP accumulation, glycerol production in adipose tissue, iNOS expression, and nitric oxide-induced cell proliferation; it can induce apoptosis in melanoma cell lines [1][3]. - **Molecular type:** Synthetic small molecule [2][8]. - It is widely used as a pharmacological tool to characterize β3-adrenergic receptor function and has been proposed as a selective radioligand for mapping β3-adrenoceptor binding sites, particularly in human tissue due to its high selectivity and affinity [3][10]. - There is no evidence of clinical development or approval for therapeutic use; it is primarily a research compound for pharmacological and receptor characterization studies [2][8][10]. - **CAS Number:** 244192-94-7 - **Developer:** Not explicitly specified. The compound is sold by research biochemical companies such as Cayman Chemical and R&D Systems [1][4].

Other names

N-[[3-[(2S)-2-hydroxy-3-[2-[4-(phenylsulfonylamino)phenyl]ethylamino]propoxy]phenyl]methyl]acetamide244192-94-7